David S. Goldberg, Tamar H. Taddei, Marina Serper, Rajni Mehta, Eric Dieperink, Ayse Aytaman, Michelle Baytarian, Rena Fox, Kristel Hunt, Marcos Pedrosa, Christine Pocha, Adriana Valderrama, David E Kaplan – 17 August 2016 – Hepatocellular carcinoma (HCC) is a leading cause of morbidity and mortality in cirrhosis patients. This provides an opportunity to target the highest‐risk population, yet surveillance rates in the United States and Europe range from 10% to 40%.

Frédéric Le Gal, Ségolène Brichler, Roland Sahli, Sylvie Chevret, Emmanuel Gordien – 17 August 2016 – Infection by the hepatitis delta virus (HDV), a satellite of the hepatitis B virus (HBV), increases viral liver disease severity. Its diagnosis is thus vital for HBV‐infected patients. HDV‐RNA load (HDVL) should be assessed and monitored in plasma using real‐time reverse‐transcriptase polymerase chain reaction assays.

Jiabei Wang, Changming Xie, Shangha Pan, Yingjian Liang, Jihua Han, Yaliang Lan, Jing Sun, Keyu Li, Boshi Sun, Guangchao Yang, Huawen Shi, Yuejin Li, Ruipeng Song, Xirui Liu, Mingxi Zhu, Dalong Yin, Huanlai Wang, Xuan Song, Zhaoyang Lu, Hongchi Jiang, Tongsen Zheng, Lianxin Liu – 17 August 2016 – Increasing evidence supports a role for N‐myc downstream‐regulated gene 2 (NDRG2) deregulation in tumorigenesis. We investigated the roles and mechanisms of NDRG2 in human cholangiocarcinoma (CCA) progression.

Sherean Farvardin, Jaimin Patel, Maleka Khambaty, Olutola A. Yerokun, Huram Mok, Jasmin A. Tiro, Adam C. Yopp, Neehar D. Parikh, Jorge A. Marrero, Amit G. Singal – 17 August 2016 – Over 20% of patients with cirrhosis are nonadherent with hepatocellular carcinoma (HCC) surveillance recommendations; however, few studies have evaluated the impact of patient‐level factors on surveillance receipt.

Elliot B. Tapper, Bruce R. Bacon, Michael P. Curry, Douglas T. Dieterich, Steven L. Flamm, Lauren E. Guest, Kris V. Kowdley, Yoori Lee, Naoky C. Tsai, Zobair M. Younossi, Nezam H. Afdhal – 17 August 2016 – Many patients with chronic hepatitis C virus (HCV) are on prolonged proton‐pump inhibitor (PPI) therapy and wish to remain on PPI therapy once treatment for HCV starts. A preliminary report recently suggested decrease rates of sustained virological response (SVR) for patients taking concomitant PPI and ledipasvir/sofosbuvir (LDV/SOF).

Luisa Salazar‐Vizcaya, Roger D. Kouyos, Cindy Zahnd, Gilles Wandeler, Manuel Battegay, Katharine Elizabeth Anna Darling, Enos Bernasconi, Alexandra Calmy, Pietro Vernazza, Hansjakob Furrer, Matthias Egger, Olivia Keiser, Andri Rauch, the Swiss HIV Cohort Study – 17 August 2016 – The incidence of hepatitis C virus (HCV) infections among human immunodeficiency virus (HIV)‐infected men who have sex with men has increased in recent years and is associated with high‐risk sexual behavior.

Hirohisa Okabe, Jing Yang, Kyle Sylakowski, Mladen Yovchev, Yoshitaka Miyagawa, Shanmugam Nagarajan, Maria Chikina, Michael Thompson, Michael Oertel, Hideo Baba, Satdarshan P Monga, Kari Nichole Nejak‐Bowen – 17 August 2016 – Hepatic repair is directed chiefly by the proliferation of resident mature epithelial cells. Furthermore, if predominant injury is to cholangiocytes, the hepatocytes can transdifferentiate to cholangiocytes to assist in the repair and vice versa, as shown by various fate‐tracing studies. However, the molecular bases of reprogramming remain elusive.

Jie Wang, Hyoung‐Won Koh, Lu Zhou, Ui‐Jin Bae, Hwa‐Suk Lee, In Hyuk Bang, Sun‐O Ka, Seon‐Hee Oh, Eun Ju Bae, Byung‐Hyun Park – 17 August 2016 – Sirtuin 2 (Sirt2) is known to negatively regulate anoxia‐reoxygenation injury in myoblasts. Because protein levels of Sirt2 are increased in ischemia‐reperfusion (I/R)‐injured liver tissues, we examined whether Sirt2 is protective or detrimental against hepatic I/R injury. We overexpressed Sirt2 in the liver of C57BL/6 mice using a Sirt2 adenovirus.

Laure‐Alix Clerbaux, Rita Manco, Isabelle Leclercq – 12 August 2016

Hee Ho Chu, Nam‐Joon Yi, Hyo‐Cheol Kim, Kwang‐Woong Lee, Kyung‐Suk Suh, Hwan Jun Jae, Jin Wook Chung – 12 August 2016 – The purpose of this study was to evaluate the longterm outcomes of stent placement for a hepatic venous outflow obstruction in adult liver transplantation recipients. From June 2002 to March 2014, 23 patients were confirmed to have a hepatic venous outflow obstruction after liver transplantation (18 of 789 living donors [2.3%] and 5 of 449 deceased donors [1.1%]) at our institute.